300 related articles for article (PubMed ID: 26943168)
1. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.
Tsuge M; Hiraga N; Uchida T; Kan H; Miyaki E; Masaki K; Ono A; Nakahara T; Abe-Chayama H; Zhang Y; Naswa MG; Kawaoka T; Miki D; Imamura M; Kawakami Y; Aikata H; Ochi H; Hayes CN; Chayama K
J Gastroenterol; 2016 Nov; 51(11):1073-1080. PubMed ID: 26943168
[TBL] [Abstract][Full Text] [Related]
2. Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine.
Zhang L; Gui XE; Teter C; Zhong H; Pang Z; Ding L; Li F; Zhou Y; Zhang L
Vaccine; 2014 Oct; 32(46):6091-7. PubMed ID: 25240752
[TBL] [Abstract][Full Text] [Related]
3. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
van Nunen AB; de Man RA; Heijtink RA; Vossen AC; Schalm SW
J Viral Hepat; 2002 May; 9(3):221-8. PubMed ID: 12010511
[TBL] [Abstract][Full Text] [Related]
4. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
[TBL] [Abstract][Full Text] [Related]
5. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
Stärkel P; Stoffel M; Lerut J; Horsmans Y
Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin.
Terrault NA; Zhou S; Combs C; Hahn JA; Lake JR; Roberts JP; Ascher NL; Wright TL
Hepatology; 1996 Dec; 24(6):1327-33. PubMed ID: 8938155
[TBL] [Abstract][Full Text] [Related]
7. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.
Rosenau J; Kreutz T; Kujawa M; Bahr MJ; Rifai K; Hooman N; Finger A; Michel G; Nashan B; Kuse ER; Klempnauer J; Tillmann HL; Manns MP
J Hepatol; 2007 Apr; 46(4):635-44. PubMed ID: 17316869
[TBL] [Abstract][Full Text] [Related]
8. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis.
Roche B; Feray C; Gigou M; Roque-Afonso AM; Arulnaden JL; Delvart V; Dussaix E; Guettier C; Bismuth H; Samuel D
Hepatology; 2003 Jul; 38(1):86-95. PubMed ID: 12829990
[TBL] [Abstract][Full Text] [Related]
9. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Chevaliez S; Hézode C; Bahrami S; Grare M; Pawlotsky JM
J Hepatol; 2013 Apr; 58(4):676-83. PubMed ID: 23219442
[TBL] [Abstract][Full Text] [Related]
10. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study.
De Simone P; Romagnoli R; Tandoi F; Carrai P; Ercolani G; Peri E; Zamboni F; Mameli L; Di Benedetto F; Cillo U; De Carlis L; Lauterio A; Lupo L; Tisone G; Prieto M; Loinaz C; Mas A; Suddle A; Mutimer D; Roche B; Wartenberg-Demand A; Niemann G; Böhm H; Samuel D
Transplantation; 2016 Jul; 100(7):1507-12. PubMed ID: 27023394
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
12. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
[TBL] [Abstract][Full Text] [Related]
13. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance.
Seto WK; Tanaka Y; Wong DK; Shinkai N; Cheung KS; Liu KS; Fung J; Lai CL; Yuen MF
Liver Int; 2016 May; 36(5):642-50. PubMed ID: 26474013
[TBL] [Abstract][Full Text] [Related]
15. A pilot study on the combined therapy of granulocyte-macrophage colony-stimulating factor and hepatitis B vaccine on chronic hepatitis B virus carrier children.
Wang J; Zhu Q; Zhang T; Yu H
Chin Med J (Engl); 2002 Dec; 115(12):1824-8. PubMed ID: 12622932
[TBL] [Abstract][Full Text] [Related]
16. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
Zhang TY; Guo XR; Wu YT; Kang XZ; Zheng QB; Qi RY; Chen BB; Lan Y; Wei M; Wang SJ; Xiong HL; Cao JL; Zhang BH; Qiao XY; Huang XF; Wang YB; Fang MJ; Zhang YL; Cheng T; Chen YX; Zhao QJ; Li SW; Ge SX; Chen PJ; Zhang J; Yuan Q; Xia NS
Gut; 2020 Feb; 69(2):343-354. PubMed ID: 30926653
[TBL] [Abstract][Full Text] [Related]
17. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
[TBL] [Abstract][Full Text] [Related]
18. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
19. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
20. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
